Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Up 63.7% in February

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 122,600 shares, a growth of 63.7% from the February 13th total of 74,900 shares. Currently, 6.1% of the company’s stock are sold short. Based on an average trading volume of 395,100 shares, the days-to-cover ratio is presently 0.3 days.

Analyst Ratings Changes

Several analysts have recently issued reports on APTO shares. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Aptose Biosciences in a report on Wednesday, February 12th. StockNews.com started coverage on shares of Aptose Biosciences in a research note on Wednesday, March 5th. They issued a “sell” rating for the company. Finally, Alliance Global Partners raised Aptose Biosciences to a “strong-buy” rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Aptose Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $130.00.

Aptose Biosciences Stock Performance

Aptose Biosciences stock opened at $3.69 on Friday. The stock has a market capitalization of $7.90 million, a P/E ratio of -1.24 and a beta of 1.14. Aptose Biosciences has a 52 week low of $2.39 and a 52 week high of $51.61. The stock has a 50-day simple moving average of $5.13 and a 200 day simple moving average of $8.10.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp increased its stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the quarter. Sigma Planning Corp owned 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent reporting period. 26.62% of the stock is currently owned by institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.